1 unchanged sentence
(c) Director and Section 16 Officer Rule 10b5-1 Trading Arrangements
−Removed: No director or Section 16 officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K, during the three months ended August 31, 2025.
+Added: On February 3, 2026 , Hans van Houte , Chief Financial Officer of the Company, entered into a prearranged trading plan intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (van Houte Plan), providing for the potential sale of up to 173,860 shares of the Company’s common stock, including shares issuable upon the exercise of option awards previously granted to Mr.
+Added: van Houte and shares to be acquired upon the vesting and settlement of restricted stock units previously granted to Mr.
+Added: The shares will be sold at the times and prices specified in the van Houte Plan.
+Added: The van Houte Plan expires on April 30, 2027 , or upon the earlier completion of all authorized transactions thereunder.
+Added: On February 27, 2026 , Gwenn M.
+Added: Hansen , Chief Scientific Officer of the Company, entered into a prearranged trading plan intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (Hansen Plan), providing for the potential sale of up to 52,460 shares of the Company’s common stock, including shares issuable upon the exercise of option awards previously granted to Dr.
+Added: Hansen and shares to be acquired upon the vesting and settlement of restricted stock units previously granted to Dr.
+Added: The shares will be sold at the times and prices specified in the Hansen Plan.
+Added: The Hansen Plan expires on May 31, 2027 , or upon the earlier completion of all authorized transactions thereunder.
+Added: No other director or Section 16 officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K, during the three months ended February 28, 2026.
Incorporated by Reference Filed or Furnished Herewith
1 unchanged sentence
Exhibit Filing Date
+Added: 10.1 Amendment No.
+Added: 3 to the Equity Distribution Agreement, dated March 6, 2026, by and between the Registrant and Piper Sandler & Co.
+Added: 8-K 001-39398 10.1 March 6, 2026
31.1 Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
12 unchanged sentences
NURIX THERAPEUTICS, INC.
−Removed: October 9, 2025
+Added: April 8, 2026
/s/ A RTHUR T.
2 unchanged sentences
(Principal Executive Officer)
−Removed: October 9, 2025
+Added: April 8, 2026
/s/ H ANS VAN H OUTE
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.